Exposé: DEA's Marijuana Licensing Scheme Exposed
A recently disclosed memorandum of understanding between the DEA and a registered marijuana cultivator has revealed a fatal flaw in America's cannabis research policy.
Newly uncovered DEA agreements confirm that the agency's own rules make it impossible for any company to legally produce pharmaceutical-grade cannabis for FDA-authorized clinical research.
MMJ BioPharma Cultivation has argued for years that the DEA's rules are a contradiction, blocking FDA-approved cannabis medicine.
This revelation supports MMJ BioPharma Cultivation's case, exposing why legitimate science has been paralyzed for nearly a decade.
Author's summary: DEA's rules hinder cannabis research.
More News
- The Future Of Education In An AI-Driven World
- UK Championship day three updates
- World Champion Zhao advances in UK Championship
- The AI-driven company: conclusion
- A Data-Driven Framework for Influencer Marketing Success
- Radiohead postpone shows due to Thom Yorke’s extreme throat infection
- Ooredoo Expands Microsoft 365 Copilot Licensing to Boost AI-Driven Productivity
- 25% Off All Redmen Merch — Hoodies, T-Shirts, Mugs, and More
- Russia's Central Bank Links Gold Demand to G7 Efforts Over Frozen Assets
- Driven adjective - meaning, pronunciation, and idiomatic use explained